Should You Continue to Retain OMCL Stock in Your Portfolio Now?
(TMDX) - Analyzing TransMedics Gr's Short Interest
Why Shares of TransMedics Stock Plunged This Week
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
TD Cowen analyst Josh Jennings maintains $TransMedics(TMDX.US)$ with a buy rating, and maintains the target price at $175.According to TipRanks data, the analyst has a success rate of 55.5% and a
TransMedics Group: A Strong Buy on Steady Transplant Volume Growth and Market Potential
Should You Consider Retaining ZBH Stock in Your Portfolio Now?